Mapping PD-1 inhibitors’ side effects using patient reported outcomes (PRO)

Data from the Belong PPN successfully captured the spectrum of PD-1 inhibitors’ reported AEs. Analyzing PRO of post approval treatments could provide deeper understanding of treatment patterns, expose limiting AE that bear implications on cost of treatment, indicate patients’ quality of life (QOL), improve management recommendations and provide a comprehensive outlook of patients’ outcomes.

Click here to download a PDF version of this study.

Immuno-poster700K-768x1086